Trial Profile

A Phase IB Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Hematologic Malignancies

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 14 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Birabresib (Primary)
Indications Acute myeloid leukaemia; Diffuse large B cell lymphoma
Focus Adverse reactions
Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

29 Sep 2021 Status changed from active, no longer recruiting to discontinued due to limited efficacy and not due to safety reasons.
12 Jul 2021 Planned End Date changed from 30 Jun 2021 to 31 Dec 2021.
06 Jan 2021 Planned End Date changed from 31 Dec 2020 to 30 Jun 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com